Orum Therapeutics, Inc. (KOSDAQ:475830)

South Korea flag South Korea · Delayed Price · Currency is KRW
35,050
+1,200 (3.55%)
Oct 10, 2025, 3:30 PM KST
3.55%
Market Cap741.61B
Revenue (ttm)20.88B
Net Income (ttm)-8.83B
Shares Out21.16M
EPS (ttm)-675.12
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume219,663
Average Volume201,212
Open34,200
Previous Close33,850
Day's Range34,150 - 36,600
52-Week Range15,950 - 42,250
Betan/a
RSI62.83
Earnings DateNov 14, 2025

About Orum Therapeutics

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company focuses on degrader-antibody conjugate that combine antibody-drug conjugate with targeted protein degradation technology. Its lead product candidate is ORM-1153, a GSPT1 protein degrader that targets hematologic malignancies. The company was founded in 2016 and is based in Daejeon, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 475830
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.